Introduction of PandaOmics for Target Discovery in Amyotrophic Lateral Sclerosis patients @InsilicoMedicine
Introduction of PandaOmics for Target Discovery in Amyotrophic Lateral Sclerosis patients @InsilicoMedicine
Uploaded August 2021 | Updated September 2026, 1 week ago
Insilico Medicine introduces the use of AI-based platform, PandaOmics, for target discovery in Amyotrophic Lateral Sclerosis (ALS) patients.
To read more about the story, please visit: als.ai

Follow us on LinkedIn: linkedin.com/showcase/pandaomics
For more information about the platform visit: insilico.com/pandaomics
Introduction of PandaOmics for Target Discovery in Amyotrophic Lateral Sclerosis patientsKOLs Interview Series: Dr. Charles CantorCGTN Live with Alex ZhavoronkovPandaOmics 3.0 - the tool for OMICS Data Analysis, Pathway Analysis and Visualization, and Target IDAI-Unleashed - Docuthon Honorable MentionStory of Rentosertib ISM001-055ARDD is about to start - things to knowKOLs Interview Series: Dr. Yuri NikolskyGrand Opening of Insilico Medicines Generative AI and Quantum Computing R&D Center in Abu DhabiInsilico Medicines AI-Powered Robotics LabTour Insilico Medicines AI-Powered Robotics LabPaper Decoding | Finding dual-purpose targets for aging and disease using PandaOmics
Insilico Medicine |

Introduction of PandaOmics for Target Discovery in Amyotrophic Lateral Sclerosis patients

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER